CG Oncology (NASDAQ: CGON) revenue
CG Oncology reported revenue of $4.0m for fiscal 2025, 254.7% more than in fiscal 2024 ($1.1m). Since fiscal 2023 its revenue has grown by 1,880.4%, an average growth of 345.0% a year.
CG Oncology has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 3 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $4.0m | +254.7% | −$190.8m | −4,722.1% |
| 2024 | $1.1m | +458.3% | −$114.7m | −10,067.3% |
| 2023 | $0.2m | — | −$55.4m | −27,180.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
CG Oncology revenue compared with its sector
By revenue for its latest fiscal year, CG Oncology ranks 384th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; CG Oncology, 254.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 382nd | Prime Medicine | $4.6m | 55.3% |
| 383rd | Ocugen | $4.4m | 8.8% |
| 384th | CG Oncology | $4.0m | 254.7% |
| 385th | Crispr Therapeutics AG | $3.5m | −90.6% |
| 386th | CAMP4 Therapeutics | $3.5m | 436.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of CG Oncology
- How much revenue did CG Oncology make in fiscal 2025?
- CG Oncology reported revenue of $4.0m for fiscal 2025, compared with $1.1m in fiscal 2024.
- How much has the revenue of CG Oncology grown?
- Between fiscal 2023 and fiscal 2025 it went from $0.2m to $4.0m: 1,880.4% more, an average growth of 345.0% a year.
- What was the best year for revenue at CG Oncology?
- Of its last 3 fiscal years, fiscal 2025, with $4.0m.
- Where does CG Oncology rank in its sector by revenue?
- It ranks 384th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for CG Oncology come from?
- From the annual report (Form 10-K) that CG Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that CG Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on CG Oncology: the CG Oncology page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.